The biotech startup EraCal Therapeutics Ltd. develops a novel anti-obesity drug with superior efficacy and safety in zebrafish, mice, and rats compared to the standard of care (lorcaserin). Our zebrafish-based phenotypic platform enabled new target discovery and is applicable to other indications.
Cooperation possibilities
In vivo drug discovery and/or validation, CNS active compounds, small molecule chemistry
